Oramed Pharmaceuticals Inc. — Form 10-Q Summary
Business context and period: Development-stage biotechnology company focused on oral delivery of insulin and other polypeptides. This Form 10-Q reports the quarter and six months ended February 29, 2012, within fiscal 2012. The company had no revenue from planned operations.
Financial results and position
- Six months: R&D expense was $894,663, up from $627,816; G&A expense was $511,605, down from $621,016. Net loss was $1,463,894 versus $1,245,575; basic and diluted loss per share was $0.02 in both periods.
- Three months: R&D expense was $710,647 versus $341,328; G&A expense was $229,704 versus $305,887. Net loss was $985,375 versus $642,791; loss per share was $0.01 in both periods.
- Cash flow: Operating activities used $1,094,760 in the six months, compared with $695,402 used a year earlier. Investing activities provided $1,405,536, principally from short-term deposits and the $450,000 Entera investment sale proceeds. There were no financing cash flows in the period.
- Liquidity: At February 29, cash and cash equivalents were $1,824,141, short-term deposits $838,738, and marketable securities $341,454. Current assets were $3,108,283, versus current liabilities of $582,159. Total assets were $3,142,588 and stockholders’ equity was $2,398,393.
- Debt and margins: No interest-bearing debt is shown on the February 29 balance sheet. With no revenue, operating and gross margins are not meaningful.
- Other items: The company recorded a $43,111 impairment of available-for-sale securities. The accumulated development-stage deficit was $16,011,193.
Material changes and outlook
- R&D spending increased, mainly due to preparation for a planned FDA Phase 2 study and the end of prior OCS grant support; lower stock-based compensation partly offset the increase. G&A declined, primarily due to lower professional fees, partly offset by higher investor-relations costs.
- Management estimated spending of approximately $5.687 million for the 12 months beginning March 1, 2012, including $4.57 million for R&D and $1.118 million for G&A. It stated existing cash resources were insufficient to meet projected needs through February 28, 2013.
- The company planned to submit an IND application for oral insulin in the fourth calendar quarter of 2012, with an FDA-approved Phase 2 study intended to follow if circumstances permit. Progress depends on financing and possible additional OCS funding; approval of a requested OCS grant was not assured.
- Management was pursuing public or private equity financing and discussions with investors and existing shareholders. The filing states substantial doubt exists about the company’s ability to continue as a going concern; the financial statements include no adjustments that might be required if it cannot continue.
- Business risks include clinical and regulatory uncertainty, the need for additional capital, dependence on third-party suppliers and service providers, and uncertainty around patent protection. The filing reports no material legal proceedings.
- Management identified a material weakness in disclosure controls related to segregation of duties: the CFO was the only qualified internal accounting and financial-reporting employee, without independent checks or backup. No material changes in internal control were reported during the quarter.
Important facts for investors to verify
- Whether the company secured sufficient financing to fund its stated approximately $5.7 million 12-month spending plan and address the going-concern uncertainty.
- Whether the planned fourth-quarter 2012 IND submission and subsequent Phase 2 study proceeded, and whether regulatory or clinical developments changed the timeline.
- Whether additional OCS support was approved and how grant funding affected R&D spending and future royalty obligations.
- The status and valuation of the D.N.A Biomedical marketable securities, including the recorded impairment.
- Progress in remediating the disclosed segregation-of-duties material weakness and the effect of subsequent share issuances and equity-based advisory arrangements.